孟祥银,杨波,祝起禛,梁永广,周震,邱杰.立体定向放疗计划验证模体在脑转移瘤HyperArc技术中的应用研究[J].中华放射医学与防护杂志,2023,43(12):991-996
立体定向放疗计划验证模体在脑转移瘤HyperArc技术中的应用研究
Application of stereotactic body radiotherapy planning verification phantom in HyperArc technique for brain metastases
投稿时间:2023-03-17  
DOI:10.3760/cma.j.cn112271-20230317-00082
中文关键词:  StereoPhan模体  SRS MapCHECK半导体矩阵  HyperArc  剂量验证
英文关键词:StereoPhan phantom  SRS MapCHECK semiconductor matrix  HyperArc  Dose verification
基金项目:国家重点研发计划资助(2022YFC2404606);中央高水平医院临床科研业务费资助项目(2022-PUMCH-B-116)
作者单位E-mail
孟祥银 中国医学科学院北京协和医学院北京协和医院放射治疗科, 北京 100730  
杨波 中国医学科学院北京协和医学院北京协和医院放射治疗科, 北京 100730  
祝起禛 中国医学科学院北京协和医学院北京协和医院放射治疗科, 北京 100730  
梁永广 中国医学科学院北京协和医学院北京协和医院放射治疗科, 北京 100730  
周震 中国医学科学院北京协和医学院北京协和医院放射治疗科, 北京 100730  
邱杰 中国医学科学院北京协和医学院北京协和医院放射治疗科, 北京 100730 qiujie@pumch.cn 
摘要点击次数: 765
全文下载次数: 272
中文摘要:
      目的 探究StereoPhan(SP)模体与SRS MapCHECK(SMC)半导体矩阵用于脑转移瘤患者HyperArc(HA)计划剂量验证的可行性。方法 选取16例在北京协和医院接受HA放射治疗的脑转移瘤患者为研究对象,分别将电离室和SMC半导体矩阵插入SP模体,测量患者的HA验证计划的点剂量与平面剂量,并与治疗计划系统(TPS)计算数据对比,平面剂量的γ分析标准取2 mm/3%、2 mm/2%、1 mm/3%和1 mm/2%。结果 16例患者的点剂量平均偏差是1.33%±0.84%,平面剂量γ通过率在2 mm/3%、2 mm/2%的标准下依次为99.72%±0.46%、98.93%±1.32%,在 1 mm/3% 、1 mm/2%的标准下依次为98.85%±1.79%、97.13%±3.19%。结论 SP模体与SMC半导体矩阵适合用于开展脑转移瘤患者HA计划的剂量验证工作,在进行点剂量和平面剂量验证时,可以分别采用3%和1mm/2%的分析标准。
英文摘要:
      Objective To explore the feasibility of StereoPhan (SP) phantoms and SRS MapCHECK (SMC) semiconductor matrices in the dose verification of HyperArc (HA) plans for patients with brain metastases (BM).Methods A total of 16 BM patients who received HA radiotherapy in the Peking Union Medical College Hospital were enrolled in this study. The ion chamber and the SMC semiconductor matrix were inserted into SP phantoms, respectively. The point and planar doses in HA verification plans were measured and compared with the calculated data of the treatment planning system (TPS). The criteria for planar dose γ analysis were set at 2 mm/3%, 2 mm/2%, 1 mm/3%, and 1 mm/2%.Results The mean deviation of point doses in 16 patients was 1.33%±0.84%. Based on the above criteria, the γ pass rates of planar doses were 99.72%±0.46%, 98.93%±1.32%, 98.85%±1.79%, and 97.13%±3.19%, respectively.Conclusions SP phantoms and SMC semiconductor matrices are applicable to the dose verification of HA plans for BM patients. The analytical criteria of 3% and 1 mm/2% can be used for verifying point and planar doses, respectively.
HTML  查看全文  查看/发表评论  下载PDF阅读器
关闭